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Diazepam is a benzodiazepine derivative with anxyolitic, anticonvulsant, hypnotic, 
sedative, skeletal muscle relaxant, antitremor, and amnestic activity. It is metabolized in 
the liver by the cytochrome P (CYP) 450 enzyme system. Diazepam is N-demethylated 
by CYP3A4 and CYP2C19 to the active metabolite N-desmethyldiazepam, and is 
hydroxylated by CYP3A4 to the active metabolite temazepam. N-desmethyl-diazepam 
and temazepam are both further metabolized to oxazepam. Concomitant intake of 
inhibitors or inducers of the CYP isozymes involved in the biotransformation of diazepam 
may alter plasma concentrations of this drug, although this effect is unlikely to be 
associated with clinically relevant interactions. 
The goal of this article was to review the current literature on clinically relevant 
pharmacokinetic drug interactions with diazepam. 
A search of MEDLINE and EMBASE was conducted for original research and review 
articles published in English between January 1971. and May 2011. Among the search 
terms were drug interactions, diazepam, pharmacokinetics, drug metabolism, and 
cytochrome P450. Only articles published in peer-reviewed journals were included, and 
meeting abstracts were excluded. The reference lists of relevant articles were hand-
searched for additional publications. 
Diazepam is substantially sorbed by the plastics in flexible containers, volume 
control set chambers, and tubings of intravenous administration sets. Manufacturers 
recommend not mixing with any other drug or solution in syringe or solution, although 
diazepam is compatible in syringe with cimetidine and ranitidine, and in Y-site with 
cisatracurium, dobutamine, fentanyl, hydromorphone, methadone, morphine, nafcillin, 
quinidine gluconate, remifentanil, and sufentanil. Diazepam is compatible with: dextrose 
5% in water, Ringers injection, Ringers injection lactated and sodium chloride 0.9%. 
Emulsified diazepam is compatible with Intralipid and Nutralipid. 
Diazepam has low potential for pharmacokinetic drug interactions. Although 
interactions with diazepam may be predictable in specific circumstances, when diazepam 
is used with: analgesics, anesthetics, anticonvulsants, antipsychotics, anxiolytics/sedatives, 
barbiturates, hypnotics, MAO inhibitors, narcotics, sedative anihistamines, phenothiazines 
and other antidepressants, careful consideration is needed. Acta Medica Medianae 
2011;50(2):76-82. 
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Introduction 
 
Diazepam is a benzodiazepine derivative. 
This is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-
2H-1,4-benzodiazepin-2-one. The empirical formula 
of diazepam is C16H13ClN2O and the molecular 
weight is 284.75. It is colorless to light yellow 
crystalline powder, practically odourless.  Soluble 
1 in 333 of water, 1 in 16 of alcohol, 1 in 2 of 
chloroform, and 1 in 39 of ether. A melting point 
of diazepam is 131.5 to 134.5 °C. The structural 
formula is as follows: 
 
 
 
In addition to the active ingredient diazepam, 
each tablet contains the inactive ingredients: 
anhydrous lactose, corn starch, pregelatinized 
starch and calcium stearate. 
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Mechanism of action 
 
Diazepam is a long-acting benzodiazepine 
with anticonvulsant, anxiolytic, sedative, muscle 
relaxant, and amnestic properties. Its actions are 
mediated by enhancement of the activity of 
gamma-aminobutyric acid (GABA), a major inhibitory 
neurotransmitter in the brain. Diazepam binds 
non-selectively to alpha1, alpha2, alpha3 and 
alpha5 subunits containing GABAA receptors at a 
site that is distinct from the binding site of the 
endogenous GABA molecule (1). 
 
Pharmacokinetics 
 
Diazepam is administered orally, rectally, 
and parenterally: intravenously (needs to be 
diluted, as it is painful and damaging to veins) 
and intramuscularly. 
After oral administration, diazepam is readily 
and almost completely (>90%) absorbed from 
the gastrointestinal tract. The peak plasma 
concentrations occur within about 30 to 90 
minutes of oral administration. Absorption is 
delayed and decreased when administered with a 
fat meal. Diazepam is rapidly absorbed after 
administration as a rectal solution and the peak 
plasma concentrations are achieved after about 
10 to 30 minutes.  
Intramuscular administration is followed by 
unpredictable absorption which is characterized 
with obtained lower peak plasma concentrations 
compared with those following oral administration. 
Diazepam and its metabolites are highly 
bound to plasma proteins (>95%). The volume of 
diazepam distribution at steady-state in young 
healthy males is 0.7 to 2.6 L/kg. Diazepam has a 
biphasic half-life with an initial rapid distribution 
phase (a half-life of approximately one hour) 
followed by a prolonged terminal elimination 
phase of 1 or 2 days. The action of diazepam is 
further prolonged by the even longer half-life of 2 
to 5 days of its principal active metabolite, 
desmethyldiazepam (also known as nordazepam 
or nordiazepam). The plasma elimination half-life 
of diazepam and/or its metabolites is prolonged 
in neonates, in the elderly, and in patients with 
liver disease. Diazepam accumulates upon 
multiple dosing. It is highly lipid soluble and 
passes rapidly into the brain and other well-
perfused organs, and is afterwards redistributed 
to muscle and adipose tissues. Diazepam and its 
metabolites crosses placental barriers and are 
also present in breast milk in concentrations 
approximately one tenth of those in maternal 
plasma. 
Diazepam is N-demethylated by CYP3A4 
and CYP2C19 to the active metabolite N-
desmethyldiazepam, and further hydroxylated by 
CYP3A4 to the active metabolite temazepam. 
Both N-desmethyldiazepam and temazepam are 
then metabolized to oxazepam. Temazepam and 
oxazepam are largely conjugated with glucuronide, 
and are excreted primarily in the urine. 
Indications 
 
Diazepam is used for the short-term treatment 
of severe anxiety, panic attacks and states of 
agitation, as a sedative for pre-/postoperative 
sedation, anxiolysis and/or amnesia, as a hypnotic 
in the short-term management of insomnia, as an 
anticonvulsant (status epilepticus and febrile 
convulsions), for the control of muscle spasm, 
and for the management of alcohol, opiate and 
benzodiazepine withdrawal symptoms. 
 
Contraindications 
 
Diazepam should be avoided in patients 
with pre-existing CNS depression or coma, 
respiratory depression, acute pulmonary insufficiency, 
myasthenia gravis, or sleep apnea. It should be 
carefully used in those with chronic pulmonary 
insufficiency. 
 
Interactions with diazepam in vitro 
 
Diazepam is substantially sorbed by the 
plastics in flexible containers, volume control set 
chambers, and tubings of intravenous administration 
sets. Only a small part of  diazepam may remain in 
the infused solution (2), because of the drug 
adsorption onto the walls of polyvinylchloride 
infusion sets. Administration sets should contain 
the minimum length of polyvinylchloride tubing 
and should not contain a cellulose propionate 
volume-control chamber. Diazepam solutions are 
stable in glass containers. Lack of sorption of the 
diazepam to polyolefin semi-rigid containers 
makes these alternatives acceptable (3). Suitable 
materials for infusion containers, syringes, and 
administration sets for administration of diazepam 
are: glass, polyolefin, polypropylene, and poly-
ethylene. 
Manufacturers recommend not mixing with 
any other drug or solution in syringe or solution, 
although diazepam is compatible in syringe with 
cimetidine and ranitidine, and in Y-site with 
cisatracurium, dobutamine, fentanyl, hydromorphone, 
methadone, morphine, nafcillin, quinidine gluconate, 
remifentanil, and sufentanil. Diazepam is compatible 
with: dextrose 5% in water, Ringers injection, 
Ringers injection lactated and sodium chloride 
0.9%. Emulsified diazepam is compatible with 
Intralipid and Nutralipid. 
 
Interactions with diazepam in vivo 
 
Analgesics 
 
Coadministration of dextropropoxyphene 
had no influence on diazepam volume of 
distribution. Diazepam elimination half-life was 
longer during the dextropropoxyphene trial 
compared to the control trial and total metabolic 
clearance was less, without statistically significant 
differences in healthy subjects (4). Drug interactions with diazepam            .                                                                               Zoran Bojanić et al. 
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Paracetamol produced no significant change 
in plasma concentrations of diazepam or its major 
metabolite (5). 
Diazepam may be used with opioid anal-
gesics in anaesthetic or analgesic regimens. An 
additional sedative effect is to be expected. 
Pretreatment with morphine or pethidine has 
decreased the rate of oral absorption of 
diazepam. This has been attributed to the effect 
of opioid analgesics (morphine and pethidine) on 
delay of gastric emptying so that the rate of 
absorption of diazepam is reduced (6). 
 
Antacids 
 
The concomitant use of aluminium hydro-
xide or sodium citrate hastened the onset of the 
soporific effect of diazepam marginally, while 
magnesium trisilicate tended to delay it. The 
estimation of plasma diazepam concentrations 
over 90 min showed that the absorption of 
diazepam was increased significantly by the use 
of aluminium hydroxide (7). No adverse effect of 
any clinical importance is likely during the 
treatment with antacids and diazepam together. 
 
Antibiotics 
 
Ciprofloxacin causes the increased AUC 
(area under curve) in healthy subjects by 50%, 
reduced clearance by 37%, and doubled half-life 
of diazepam. These pharmacokinetic changes 
cause no significant changes in the performance 
of a number of psychometric tests (8). 
Erythromycin increased the AUC of diazepam 
by 15%, but psychomotor effects of diazepam 
were not changed significantly. The interactions 
of erythromycin with diazepam are slight and of 
limited clinical significance (9). 
Rifampicin increased the clearance in 
healthy subjects to 300% and desmethyl- and 3-
hydroxydiazepam metabolic clearance to 400% 
(10). The mean half-life of diazepam was signi-
ficantly shorter (14 hr) in patients with tuberculosis 
treated with rifampicin than in healthy control 
subjects treated only with diazepam (58 hr) (11). 
Rifampicin is a very potent liver enzyme-inducing 
drug which increases the metabolism of diazepam 
by the liver. In patients with tuberculosis who 
take isoniazid (an enzyme inhibitor) and rifampicin, 
the enzyme- inducing effect predominates. 
 
Antiepileptics 
 
Carbamazepine, phenobarbital, and phenytoin 
are all inducers of hepatic drug-metabolising 
enzymes. The metabolism of diazepam may be 
enhanced in patients receiving long-term therapy 
with these drugs, and decrease in serum levels of 
diazepam is present (12). 
The clearance of diazepam is about 
threefold increased by carbamazepine and half-
life shorter than in healthy subjects (13). 
Diazepam has an unpredictable effect on 
phenytoin serum concentration. Metabolism of 
phenytoin may be altered by diazepam influencing 
CYP2C9 or CYP2C19. In some cases, diazepam 
significantly increases phenitoin concentrations and 
induces toxic effect of this antiepileptic drug (14-
16), but in other cases it decreases phenitoin 
serum concentrations (17,18). 
Sodium valproate increased the serum 
levels of diazepam approximately twofold. It also 
induces a significant increase in apparent volume 
of distribution and plasma clearance of diazepam. 
Valproic acid displaces diazepam from plasma 
protein binding sites and inhibits its metabolism 
(19). 
 
Antituberculotics 
 
Ethambutol does not interact with diazepam 
(11). 
Isoniazid did not alter diazepam volume of 
distribution or protein binding, but prolonged 
mean elimination half-life (t1/2) from 34 to 45 
hr, and reduced total clearance from 0.54 to 0.40 
ml/min/kg (11). Inhibition of CYP3A isoforms is 
the likely mechanism by which isoniazid slows 
the elimination of coadministered diazepam. Slow 
acetylators of isoniazid have greater risk for 
adverse drug interactions, because the degree of 
inhibition is concentration-dependent. 
 
Anticoagulants 
 
Free concentrations of diazepam and des-
methyldiazepam increase immediately after intra-
venous administration of heparin (20). 
Anticoagulant effect of warfarin is not 
affected by diazepam (21). 
 
Antidepressants 
 
Nefazodone raised plasma level of desmethyl-
diazepam 87%. Insomnia was significantly improved 
by combination of nefazodone with a diazepam (22). 
 
Antifungals 
 
Both voriconazole and fluconazole considerably 
increase the exposure to diazepam. After vori-
conazole the area under the plasma concen-
tration time curve of diazepam was increased 
2.2-fold and a prolongation of the mean 
elimination half-life was two fold. After the 
fluconazole the AUC of diazepam was increased 
2.5-fold, and the t1/2 was prolonged from 2.5-
fold. Recurrent administration of diazepam increases 
the risk of clinically significant interactions during 
voriconazole or fluconazole treatment, because the 
elimination of diazepam is significantly impaired 
(23). 
 
Atropine 
 
Atropine does not affect absorption or the 
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Beta blockers 
 
Clinically unimportant pharmacokinetic inter-
actions occur between diazepam and beta blockers. 
Only metoprolol increases AUC of diazepam  by 
25% (25). 
 
Calcium channel blockers 
 
No significant drug interactions between 
diazepam and diltiazem (26), felodipine (27) or 
nimodipine (28) have been registered. 
 
Ethanol 
 
Acute ethanol ingestion may potentiate the 
CNS effects of diazepam. Alcohol increases the 
absorption and raises the serum levels of 
diazepam. Tolerance may develop with chronic 
ethanol use. This is explained by decreased 
clearance of the diazepam because of CYP450 
hepatic enzyme inhibition. The cognitive deficits 
induced by diazepam may be increased in 
patients who chronically consume large amounts 
of alcohol. 
 
Grapefruit 
 
Grapefruit juice markedly improved the 
bioavailability of diazepam – increased the AUC 
of diazepam 3.2 fold and the maximum serum 
levels were increased 1.5 fold (29). 
 
H2 blockers 
 
Cimetidine increased plasma concentrations 
of diazepam plus desmethyldiazepam by 57%, 
but reaction times and other motor and 
intellectual tests remained unaffected (30). 
Famotidine (31), nizatidine (32), ranitidine 
(32) and roxatidine do not interact with diazepam 
(33). 
Interaction a diazepam with H2 blockers 
(even a cimetidine) has a little or no clinical 
importance. 
 
Levodopa 
 
The therapeutic effects of levodopa can be 
reduced or abolished in some patents by the 
concomitant use of diazepam (34). Some authors 
suggested administration of diazepam for sleep 
induction and maintenance in patients on 
levodopa (35). 
 
Metoclopramide 
Intravenous but not oral metoclopramide 
increases the rate of absorption (peak levels by 
30 instead of 60 min) of diazepam and raises its 
peak plasma levels by 38% (6). The clinical 
importance of this interaction is small. 
Metronidazole 
 
Metronidazole does not significantly inhibit 
the oxidative drug metabolism of diazepam 
because there is no changes in total plasma 
clearance, plasma t1/2 and volume of distribution 
of diazepam (36). 
 
Oral contraceptives 
 
Oral contraceptives may inhibit the biotrans-
formation of diazepam by oxidation and can 
increase the effects of diazepam (37). 
Diazepam can possibly increase the incidence 
of break-through bleeding (38). Psychomotor 
impairment due to oral diazepam was greater 
during the menstrual pause than during the 21-
daily oral contraceptive cycle. This may have 
been due to an effect of oral contraceptives on 
diazepam absorption (39). 
 
Penicillamine 
 
Phlebitis associated with intravenous diazepam 
resolved with local heat but recurred on two 
separate occasions after oral penicillamine (40). 
 
Proton pump inhibitors 
 
Long-term treatment with a therapeutic dose 
of lansoprazole does not interfere with the 
metabolism of diazepam (41). 
After repeated oral administration of 40 mg 
omeprazole over 7 days a prolongation of the 
elimination half-life (by 130%) and a concomitant 
decrease of the clearance of diazepam (by 54%) 
were registered. Omeprazole did not affect the 
volume of distribution and the plasma protein 
binding of diazepam (42). This effect was only 
present in omeprazole extensive metabolizers 
who represent the majority (95%) of the 
Caucasian population (43). 
Pantoprazole and diazepam may be admini-
stered concomitantly without dose adjustment 
even when high doses of pantoprazole are 
required (44). 
Rabeprazole does not interact with diazepam 
(45). 
Interaction of diazepam with proton pump 
inhibitors has no clinical importance and only 
administration of omeprazol increases plasma 
concentration and elimination of diazepam half-
life. 
 
Tobacco smoking 
 
Drowsiness as a side-effect of diazepam is 
less frequently found in smokers than in non-
smokers (46). Reduced clinical sensitivity to 
diazepam among cigarette smokers is not directly 
related to alterations in diazepam pharmaco-
kinetics because differences in volume of 
distribution, elimination half-life, total AUC, total 
clearance, and free fraction did not approach 
significance (47). Drug interactions with diazepam            .                                                                               Zoran Bojanić et al. 
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Xantines 
 
The aminophylline given intravenously 
reversed the sedation from intravenous diazepam 
(48,49). The aminophylline-treated patients showed 
a significantly more rapid reversal of sedation, 
but after 30 minutes there was no difference 
between the two groups. The aminophylline 
antagonizes the sedative effect of benzodiazepine, 
but in routine diazepam sedation, aminophylline 
will not shorten the necessary observation period 
after sedation (50). Blockade of adenosine receptors 
by aminophylline is a possible mechanism of this 
interaction (51). 
The coadministration of caffeine with diazepam 
resulted in a 22% reduction in diazepam plasma 
levels (52). 
Xanthine-containing beverages (tea or coffee) 
may be expected to decrease the incidence of 
diazepam-induced drowsiness due to both their 
CNS-stimulating effects and hepatic drug-meta-
bolising enzymes induction. Drowsiness is reported 
less frequently in patients who are heavy coffee 
users, smoking less than or equal to 1 pack of 
cigarettes/day, while drowsiness is reported more 
frequently in patients who are heavy coffee users, 
smoking more than 1 pack of cigarettes/day. 
Similarly, drowsiness occurs less frequently among 
heavier smokers drinking less than or equal to 2 
cups of coffee/day, while drowsiness occurs more 
frequently among heavier smokers drinking more 
than 2 cups of coffee/day (53). 
 
Conclusions 
 
Diazepam is substantially sorbed by the 
plastics in flexible containers, volume control set 
chambers, and tubings of intravenous administration 
sets. Manufacturers recommend not mixing with 
any other drug or solution in syringe or solution, 
although diazepam is compatible in syringe with 
cimetidine and ranitidine, and in Y-site with 
cisatracurium, dobutamine, fentanyl, hydromorphone, 
methadone, morphine, nafcillin, quinidine gluconate, 
remifentanil, and sufentanil. Diazepam is compatible 
with: dextrose 5% in water, Ringers injection, 
Ringers injection lactated and sodium chloride 
0.9%. Emulsified diazepam is compatible with 
Intralipid and Nutralipid. 
Diazepam has low potential for pharmaco-
kinetic drug interactions. Although interactions 
may be predictable in specific circumstances, use 
of diazepam need careful consideration wth as 
analgesics, anesthetics, anticonvulsants, anti-
psychotics, anxiolytics/sedatives, barbiturates, 
hypnotics, MAO inhibitors, narcotics, sedative 
anihistamines, phenothiazines, and other anti-
depressants.
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INTERAKCIJE LEKOVA SA DIAZEPAMOM 
 
Zoran Bojanić, Novica Bojanić, Vladmila Bojanić i Marko Lazović 
 
 
  Diazepam je derivat benzodiazepina sa anksiolitičkim, antikonvulzivnim, 
hipnotičkim, sedativnim, antitremorskim, amnezijskim i miorelaksantnim delovanjem na 
skeletne mišiće. Diazepam se metaboliše u jetri pomoću citohroma P (CIP) 450 
enzimskog sistema.  Diazepam N-demetilišu CIP3A4 i CIP2C19 do aktivnog metabolita 
N-dezmetildiazepama, a pomoću CIP3A4 se hidroksiliše do aktivnog metabolita 
temazepama. I N-dezmetildiazepam i temazepam se dalje metabolišu u oksazepam. 
Istovremeni unos inhibitora ili induktora CIP izoenzima uključenih u biotransformaciju 
diazepama može da promeni plazmatske koncentracije tog leka, mada je malo 
verovatno da se taj efekat ispolji klinički relevantnim interakcijama. 
Cilj ovog rada je da se revijski prikažu klinički relevantne farmakokinetske 
interakcije sa diazepamom.  
Izvršena je pretraga originalnih istraživanja i članaka objavljenih na engleskom 
jeziku u periodu između januara 1971. i maja 2011. godine na MEDLINE i EMBASE 
bazama podataka. Za pretragu su korišćeni termini: interakcije lekova, diazepam, 
farmakokinetika, metabolizam leka i citohrom P450. Uključeni su samo članci objavljeni 
u stručnim  časopisima sa recenzijom, a apstrakti sa kongresa nisu uzimani u obzir. 
Ručnom pretragom referentnih lista relevantnih tekstova tražene su dodatne publikacije. 
Diazepam znatno apsorbuje mekana plastika od koje se pravi ambalaža, setovi za 
kontrolu volumena protoka leka i cevi setova za intravensku infuziju. Proizvođači 
preporučuju da se diazepam ne meša ni sa jednim drugim lekom u rastvoru ili špricu. 
Ipak, diazepam je kompatibilan sa cimetidinom i ranitidinom u špricu, a u Y sistemu za 
infuziju kompatibilan je sa cisatrakurijumom, dobutaminom, fentanilom, hidromorfonom, 
hinidin glukonatom, metadonom, morfinom, nafcilinom, remifentanilom i sufentanilom. 
Diazepam je kompatibilan sa 5% vodenim rastvorom dekstroze, injekcijama Ringerovog 
rastvora i injekcijama laktatnog Ringera, kao i 0,9% rastvorom natrijum hlorida. 
Emulgovani diazepam je kompatibilan sa Intralipidom i Nutralipidom. 
Diazepam ima slab potencijal za farmakokinetske interakcije lekova. Iako se 
interakcije lekova sa diazepamom mogu predvideti u specifičnim okolnostima, primenu 
tog leka treba pažljivo razmotriti pri davanju sa: analgeticima, anksioliticima/sedativima, 
antikonvulzivima, antipsihoticima, barbituratima, fenotiazinima, hipnoticima, MAO 
inhibitorima, narkoticima, sedativnim antihistaminicima i drugim antidepresivima. Acta 
Medica Medianae 2011;50(2):76-82. 
 
Ključne reči: diazepam, interakcije lekova, metabolizam lekova 